 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...79808182838485868788899091» |
- | Enrollment open: Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment (clinicaltrials.gov) - Feb 17, 2017
P4, N=500, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting --> Recruiting
- ||||| levofloxacin / Generic mfg.
Enrollment closed: Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Feb 15, 2017
P3, N=740, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- levofloxacin / Generic mfg.
Enrollment closed, Combination therapy: Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (clinicaltrials.gov) - Feb 15, 2017
P2, N=111, Active, not recruiting, Sponsor: Boston University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
Enrollment change: Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori (clinicaltrials.gov) - Feb 14, 2017
P4, N=400, Not yet recruiting, Sponsor: Damascus Hospital
Recruiting --> Active, not recruiting N=800 --> 400
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: SMILE: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization (clinicaltrials.gov) - Feb 8, 2017
P4, N=60, Recruiting, Sponsor: Zhongshan Ophthalmic Center, Sun Yet-san University
- Trial primary completion date: Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Feb 7, 2017
P4, N=200, Recruiting, Sponsor: Zahra Vahdat Shariatpanahi
N=800 --> 400 Trial primary completion date: Jan 2017 --> Apr 2017
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
Enrollment change: Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori (clinicaltrials.gov) - Feb 7, 2017
P4, N=74, Active, not recruiting, Sponsor: Damascus Hospital
Trial primary completion date: Jan 2017 --> Apr 2017 N=100 --> 74
- | Enrollment open, Trial initiation date: endTB: Evaluating Newly Approved Drugs for Multidrug-resistant TB (clinicaltrials.gov) - Feb 7, 2017
P3, N=750, Recruiting, Sponsor: M
N=100 --> 74 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Dec 2016
- Gatiflox (gatifloxacin) / Orient Europharma, Besivance (besifloxacin ophthalmic suspension) / Bausch Health
Trial primary completion date: Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (clinicaltrials.gov) - Feb 2, 2017
P3, N=252, Recruiting, Sponsor: University Hospital, Geneva
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Dec 2016 Trial primary completion date: Mar 2017 --> Mar 2018
- | Xefo (lornoxicam) - Old API Wind / down, Takeda, Vesicare (solifenacin) / Astellas
New P4 trial, Adverse events: Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? (clinicaltrials.gov) - Jan 30, 2017
P4, N=150, Recruiting, Sponsor: Mansoura University
- |||||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
New P3 trial: IGNITE3: Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (clinicaltrials.gov) - Jan 26, 2017
P3, N=1200, Recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
- | levofloxacin / Generic mfg., clarithromycin / Generic mfg.
New P4 trial: Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori (clinicaltrials.gov) - Jan 17, 2017
P4, N=800, Not yet recruiting, Sponsor: Damascus Hospital
- levofloxacin / Generic mfg., prulifloxacin / Generic mfg.
Trial completion, Trial primary completion date: FLOR: Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD (clinicaltrials.gov) - Jan 12, 2017
P4, N=258, Completed, Sponsor: Fadoi Foundation, Italy
Trial primary completion date: Mar 2017 --> Mar 2018 Recruiting --> Completed | Trial primary completion date: Nov 2012 --> Nov 2013
- |||| levofloxacin / Generic mfg.
Trial primary completion date: Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Jan 5, 2017
P3, N=740, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Nov 2012 --> Nov 2013 Trial primary completion date: Dec 2016 --> Jun 2017
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
Enrollment closed: Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori (clinicaltrials.gov) - Dec 28, 2016
P4, N=100, Active, not recruiting, Sponsor: Damascus Hospital
Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Active, not recruiting
- || levofloxacin / Generic mfg., amoxycillin/clavulanate / Generic mfg.
New P3 trial: Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study (clinicaltrials.gov) - Dec 27, 2016
P3, N=142, Not yet recruiting, Sponsor: All India Institute of Medical Sciences, New Delhi
- levofloxacin / Generic mfg.
Phase classification: Enteroaggregative E.Coli (EAEC) (clinicaltrials.gov) - Dec 27, 2016
P1, N=5, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P1
- Sirturo (bedaquiline) / J&J, Pharmstandard
Trial primary completion date: An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (clinicaltrials.gov) - Dec 23, 2016
P2, N=5, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Phase classification: P=N/A --> P1 Trial primary completion date: Nov 2016 --> Jul 2018
- | New P4 trial: Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment (clinicaltrials.gov) - Dec 9, 2016
P4, N=480, Not yet recruiting, Sponsor: Shandong University
- | Vabomere (meropenem/vaborbactam) / Melinta Therap
Trial initiation date: Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP (clinicaltrials.gov) - Dec 5, 2016
P3, N=550, Completed, Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Trial primary completion date: Nov 2016 --> Jul 2018 Initiation date: Jul 2014 --> Nov 2014
- || azacitidine / Generic mfg.
New P3 trial: Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients (clinicaltrials.gov) - Dec 4, 2016
P3, N=170, Not yet recruiting, Sponsor: Sheba Medical Center
- levofloxacin / Generic mfg., tetracycline / Generic mfg.
New trial: Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection (clinicaltrials.gov) - Nov 30, 2016
P=N/A, N=120, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.
- loperamide / Generic mfg., azithromycin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea (clinicaltrials.gov) - Nov 27, 2016
P=N/A, N=384, Terminated, Sponsor: Uniformed Services University of the Health Sciences
N=510 --> 384 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Mar 2016; AWD arm was completed. ADF diarrhea arm was unable to fill completely and there are no funds remaining to continue recruiting/enrolling.
- nitazoxanide / Generic mfg.
Trial primary completion date: A Two Week Nitazoxanidebased Quadruple Regimen (clinicaltrials.gov) - Oct 18, 2016
P3, N=100, Recruiting, Sponsor: Tanta University
ADF diarrhea arm was unable to fill completely and there are no funds remaining to continue recruiting/enrolling. Trial primary completion date: Sep 2016 --> Dec 2017
- | New P4 trial: Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment (clinicaltrials.gov) - Oct 16, 2016
P4, N=500, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- prednisolone / Generic mfg., levofloxacin / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia (clinicaltrials.gov) - Oct 14, 2016
P4, N=80, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Sep 2016 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: Dec 2016 --> Dec 2017
- | levofloxacin / Generic mfg., tetracycline / Generic mfg.
New P4 trial: Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection (clinicaltrials.gov) - Oct 13, 2016
P4, N=700, Not yet recruiting, Sponsor: Shandong University
- ||||||| Zemdri (plazomicin) / Ionis, Achaogen
Trial completion: EPIC: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) (clinicaltrials.gov) - Oct 4, 2016
P3, N=609, Completed, Sponsor: Achaogen, Inc.
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- ||||| Zemdri (plazomicin) / Ionis, Achaogen
Enrollment closed, Trial primary completion date: EPIC: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) (clinicaltrials.gov) - Sep 16, 2016
P3, N=609, Active, not recruiting, Sponsor: Achaogen, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Sep 2016
- Enrollment open: Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Sep 15, 2016
P4, N=200, Recruiting, Sponsor: Zahra Vahdat Shariatpanahi
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Sep 2016 Not yet recruiting --> Recruiting
- | levofloxacin / Generic mfg.
New P4 trial, Head-to-Head: Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis (clinicaltrials.gov) - Sep 15, 2016
P4, N=3900, Recruiting, Sponsor: Beijing Chest Hospital
- | doxycycline / Generic mfg.
New P4 trial: Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy (clinicaltrials.gov) - Sep 9, 2016
P4, N=300, Recruiting, Sponsor: Sir Run Run Shaw Hospital
- Trial primary completion date: Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Sep 6, 2016
P4, N=200, Not yet recruiting, Sponsor: Zahra Vahdat Shariatpanahi
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Jan 2017
- Trial completion, Enrollment change, Trial primary completion date: Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients (clinicaltrials.gov) - Sep 2, 2016
P4, N=114, Completed, Sponsor: Chung-Tai Wu
Trial primary completion date: Sep 2016 --> Jan 2017 Enrolling by invitation --> Completed | N=200 --> 114 | Trial primary completion date: Dec 2016 --> Sep 2016
- levofloxacin / Generic mfg., doxycycline / Generic mfg.
New trial: Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia (clinicaltrials.gov) - Aug 31, 2016
P=N/A, N=55, Completed, Sponsor: King Faisal Specialist Hospital & Research Center
- Trial initiation date: Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Aug 24, 2016
P4, N=200, Not yet recruiting, Sponsor: Zahra Vahdat Shariatpanahi
Enrolling by invitation --> Completed | N=200 --> 114 | Trial primary completion date: Dec 2016 --> Sep 2016 Initiation date: Mar 2016 --> Aug 2016
- levofloxacin / Generic mfg.
Enrollment open: RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis (clinicaltrials.gov) - Aug 2, 2016
P=N/A, N=82, Recruiting, Sponsor: Fu Xing Hospital, Capital Medical University
Initiation date: Mar 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- ||| Enrollment open: A Multi-center Study for Eradication of Refractory Helicobacter Pylori (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=4428, Recruiting, Sponsor: Taizhou Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Vabomere (meropenem/vaborbactam) / Melinta Therap
Trial completion: Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP (clinicaltrials.gov) - Jun 28, 2016
P3, N=550, Completed, Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| levofloxacin / Generic mfg., cephalexin / Generic mfg., clindamycin phosphate / Generic mfg.
New P3 trial, Head-to-Head: ENVELOPE: Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. (clinicaltrials.gov) - Jun 22, 2016
P3, N=1492, Recruiting, Sponsor: Vanderbilt University
- levofloxacin / Generic mfg.
Trial primary completion date: Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD (clinicaltrials.gov) - Jun 20, 2016
P2, N=300, Recruiting, Sponsor: University of Monastir
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Dec 2016
- Invanz (ertapenem) / Merck (MSD), Timcynis (ticarcillin and clavulanic acid) / Emcure
New trial: The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=1552, Recruiting, Sponsor: University of Washington
- tobramycin/dexamethasone / Generic mfg., levofloxacin / Generic mfg.
Trial completion, Trial primary completion date: Early Changes Among FLEx, LASIK and FS-LASIK (clinicaltrials.gov) - Jun 15, 2016
P=N/A, N=75, Completed, Sponsor: Sun Yat-sen University
Trial primary completion date: Sep 2014 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016
- levofloxacin / Generic mfg., cefuroxime / Generic mfg., nitrofurantoin / Generic mfg.
New trial: The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy (clinicaltrials.gov) - Jun 4, 2016
P0, N=150, Not yet recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- | Invanz (ertapenem) / Merck (MSD)
New P2 trial: Clinical Trial Comparing ERAT vs Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis (clinicaltrials.gov) - Jun 4, 2016
P2, N=240, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- | Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard
Enrollment open, Trial initiation date: STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (clinicaltrials.gov) - Jun 1, 2016
P3, N=1155, Recruiting, Sponsor: IUATLD, Inc
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016 Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Apr 2016
- |||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Trial primary completion date: Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (clinicaltrials.gov) - May 25, 2016
P3, N=840, Active, not recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Apr 2016 Trial primary completion date: Feb 2016 --> Sep 2015
- | Vabomere (meropenem/vaborbactam) / Melinta Therap
Enrollment closed, Enrollment change: Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP (clinicaltrials.gov) - May 12, 2016
P3, N=550, Active, not recruiting, Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Trial primary completion date: Feb 2016 --> Sep 2015 Recruiting --> Active, not recruiting | N=850 --> 550
- Enrollment open: Treatment Shortening of MDR-TB Using Existing and New Drugs (clinicaltrials.gov) - May 3, 2016
P2, N=238, Recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting | N=850 --> 550 Not yet recruiting --> Recruiting
- levofloxacin / Generic mfg., tetracycline / Generic mfg.
New trial: Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test (clinicaltrials.gov) - May 3, 2016
P=N/A, N=123, Recruiting, Sponsor: Gangnam Severance Hospital